

CCR4 antagonist 3 hydrochloride Biochemical | CCR4 biochemical

CCR4 antagonist 3 hydrochloride

CATALOG #
AAA228196


PRODUCT SYNONYMS

CCR4 antagonist 3 hydrochloride; CCR4 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2174938-71-5
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	CCR4 antagonist 3 (compound 38; 50 mg/kg; PO; daily; for 40 days) significantly reduces the tumor growth[1]. CCR4 antagonist 3 (0.5 mg/kg; IV) has low clearance (CL=10.2 mL/min/kg), medium volume of distribution (V _{ss} =5.2 L/kg), a T _{1/2} of 6.9 h, and good bioavailability (%F = 29) of oral dosing in mouse[1]. CCR4 antagonist 3 has low clearance (CL=7.3 mL/min/kg), a half-life of 12.7 hr, and is 44% bioavailable in dog. CCR4 antagonist 3 has low clearance (CL=3.7 mL/min/kg), a long terminal half-life (10.7 hr), and good bioavailability (%F = 41) in cynomolgus monkey[1]. Animal Model: Six-to eight-week-old, female C57BL/6 mice with Pan02-OVA tumor[1]. Dosage: 50 mg/kg. Administration: PO; daily; for 40 days. Result: Significantly reduced the tumor growth. Animal Model: Rat and mouse[1]. Dosage: 0.5 mg/kg of IV; 2 mg/kg of PO. Administration: IV or PO. Result: Possessed medium clearance (CL=47.6 mL/min/kg) and was 49% bioavailable upon oral dosing in rat. Had low clearance (CL=10.2 mL/min/kg), medium volume of distribution (V _{ss} =5.2 L/kg), a T _{1/2} of 6.9 h, and good bioavailability (%F = 29) of oral dosing in mouse.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
BPR1R024, CAS 2503015-75-4



Structure
BPR1R024, CAS 2503015-75-4

ADDITIONAL INFORMATION

Related Product Information for CCR4 biochemical

CCR4 antagonist 3 hydrochloride is an orally active, potent and selective CCR4 antagonist. CCR4 antagonist 3, featuring a novel piperidiny-azetidine motif, has IC₅₀s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4 antagonist 3 has antitumor activity.

References

1. Lee KH, et al. Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model. J Med Chem. 2021 Oct 14;64(19):14477-14497.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://www.aaabiotech.com/biochemical/ccr4-antagonist-3-hydrochloride/228196>